MannKind Chief Medical Officer Burkhard Blank to depart; separation terms include $386K bonus

MANNKIND CORP

Burkhard Blank stepped down as CMO and EVP R&D effective May 9, 2025, becoming non-executive employee.
Last day of employment is August 1, 2025; base salary continued for 13 weeks through Oct 31, 2025.
One-time special bonus of $386,000 payable in January 2026; COBRA premiums reimbursed until Oct 31.
Equity awards continue to vest while Blank remains employed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Burkhard Blank

Chief Medical Officer and Executive Vice President, Research & Development

MNKD · MANNKIND CORP

Effective: 2025-05-14
Filed: May 15, 2025, 7:59 PM ET

On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Burkhard Blank changed role as Chief Medical Officer and Executive Vice President, Research & Development at MANNKIND CORP.

Action: stepped down
Role: Chief Medical Officer and Executive Vice President, Research & Development

Exact text from the filing

On May 9, 2025, MannKind Corporation (the “Company”) and Burkhard Blank, Chief Medical Officer and Executive Vice President, Research & Development, mutually agreed that Mr. Blank would step down from his role as an executive officer of the Company.

View on SEC.gov

MANNKIND CORP filing history →

Source: SEC EDGAR

accession 0001193125-25-120797

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.